Try our Advanced Search for more refined results

FEDERAL TRADE COMMISSION v. ENDO PHARMACEUTICALS INC. et al

  1. July 27, 2016

    Watson Pushes To Sever Lidoderm, Opana Pay-For-Delay Suits

    Watson Laboratories Inc. and its owner, Allergan PLC, on Tuesday again urged a Pennsylvania federal court to sever the Federal Trade Commission's case claiming that Watson delayed generic competition for Lidoderm from another similar case over Opana ER, saying the FTC is unable to show any logical relationship.

  2. July 13, 2016

    Drug Cos. Say Lidoderm, Opana Pay-For-Delay Suit Improper

    Allergan PLC's Watson Laboratories Inc., Endo Pharmaceuticals Inc. and Impax Laboratories Inc. on Tuesday told a Pennsylvania federal court that the Federal Trade Commission doesn't have the authority to sue them over allegedly illegal agreements to delay generics for Lidoderm and Opana ER, as there are no ongoing legal violations alleged.

  3. June 24, 2016

    Watson Wants Lidoderm, Opana Pay-For-Delay Suits Split

    Watson Laboratories Inc. and its owner Allergan PLC on Thursday asked a Pennsylvania federal court to sever the Federal Trade Commission's case claiming that it delayed generic competition for Lidoderm from another similar case over Opana ER, saying the agency was trying to merge two unrelated cases.

  4. April 07, 2016

    FTC Wins Order Barring Japan Drug Co. From Generics Deals

    A Pennsylvania federal judge issued an agreed-upon order Thursday prohibiting Japan-based Teikoku from entering any generic-drug deal that includes payment and other types of settlements, in the Federal Trade Commission's first-of-its-kind suit alleging pharmaceutical companies delayed generic competition for Opana ER and Lidoderm.

  5. March 31, 2016

    FTC Puts No-Authorized-Generic Pharma Deals In Crosshairs

    The Federal Trade Commission's first-of-its-kind enforcement action against Endo and other drugmakers lends the agency's formidable credibility to the theory that pharmaceutical companies can make anti-competitive payments by withholding authorized generics, giving a boost to private plaintiffs in similar cases, experts say.

  6. March 31, 2016

    FTC Sues Endo, Generics For Pay-For-Delay Agreements

    The Federal Trade Commission has sued Endo and other pharmaceutical companies in Pennsylvania federal court for allegedly delaying generic competition for the drugs Opana ER and Lidoderm, marking the first time the agency has sued over an agreement not to compete through an authorized generic, the FTC said Thursday.